Healios KK Ord Shs HLOSF

Healthcare Biotechnology

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

PINL:HLOSF - Post by User

Healios KK Ord Shs

<< Previous

Bullboard Posts

Post by Camaronion Jun 17, 2013 9:16am

407 Views

Post# 21531883

I guess something has changed

"QRS will consolidate its common shares into 20 million shares. QRS will then issue 20 million QRS units to the Halo shareholders in exchange for their Halo shares."

20 mil shrs dividied by our current float of 29 mil shrs = 0 .689% exchange rate per new shr after QRS shr consoildation and combining of the two companies.

<< Previous

Bullboard Posts

Options trading in a volatile macro environment